Berlin (Germany) and Germantown (USA), October 16, 2014 – Epigenomics AG (ISIN: DE000A11QW50, OTCQX: EPGNY) announces today that the Company is raising USD 5.3 million (EUR 4.2 million) in a share capital increase. BioChain Institute, Inc. will subscribe a total of 1,351,089 Epigenomics shares which will be issued under exclusion of the statutory subscription right of the shareholders.
The Executive Board of Epigenomics AG, with approval of the Supervisory Board, today resolved on the increase of the Company’s share capital by the amount of EUR 1,351,089 by issuance of 1,351,089 new shares from the Authorized Capital 2014/I against contribution in cash. The issue price has been set at EUR 3.08 per share, based on the XETRA closing price of the day prior to the announcement, Wednesday, October 15, 2014. After registration of the capital increase on or around November 21, 2014, the subscribed capital of Epigenomics AG will increase from currently EUR 13,517,558 to EUR 14,868,647.
Epigenomics AG intends to use the net proceeds from the capital increase to finance its current operations and to strengthen the distribution capabilities for its lead product Epi proColon®, a convenient blood-based test for the early detection of colorectal cancer.
– End of Ad hoc –
|Contact Epigenomics AG|
|Antje Zeise CIRO
Manager IR | PR
Phone: +49 (0) 30 24345 386
Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology, which may be sold at some future time in the U.S. have not been established.